MX2023006164A - Inhibidor de la progresion de la fibrosis. - Google Patents

Inhibidor de la progresion de la fibrosis.

Info

Publication number
MX2023006164A
MX2023006164A MX2023006164A MX2023006164A MX2023006164A MX 2023006164 A MX2023006164 A MX 2023006164A MX 2023006164 A MX2023006164 A MX 2023006164A MX 2023006164 A MX2023006164 A MX 2023006164A MX 2023006164 A MX2023006164 A MX 2023006164A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
receptor
antibody
fibrosis
progression
Prior art date
Application number
MX2023006164A
Other languages
English (en)
Spanish (es)
Inventor
Tomoyuki Fujita
Ayumi Yoshizaki
Ai Kuzumi
Shinichi Sato
Hideki Watanabe
Original Assignee
Maruho Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maruho Kk filed Critical Maruho Kk
Publication of MX2023006164A publication Critical patent/MX2023006164A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2023006164A 2020-11-30 2021-11-29 Inhibidor de la progresion de la fibrosis. MX2023006164A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/JP2020/044406 WO2022113316A1 (ja) 2020-11-30 2020-11-30 線維化の進行抑制剤
PCT/JP2021/043543 WO2022114165A1 (ja) 2020-11-30 2021-11-29 線維化の進行抑制剤

Publications (1)

Publication Number Publication Date
MX2023006164A true MX2023006164A (es) 2023-07-28

Family

ID=81754505

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023006164A MX2023006164A (es) 2020-11-30 2021-11-29 Inhibidor de la progresion de la fibrosis.

Country Status (12)

Country Link
US (1) US20240084020A1 (https=)
EP (1) EP4252771A4 (https=)
JP (3) JPWO2022113316A1 (https=)
KR (1) KR20230114698A (https=)
CN (1) CN116829187A (https=)
AU (1) AU2021385871A1 (https=)
CA (1) CA3199351A1 (https=)
CL (1) CL2023001460A1 (https=)
IL (1) IL303159A (https=)
MX (1) MX2023006164A (https=)
TW (1) TW202237182A (https=)
WO (2) WO2022113316A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5954916B1 (ja) 2015-04-14 2016-07-20 中外製薬株式会社 Il−31アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び/又は治療用医薬組成物
MX2022005654A (es) 2019-11-20 2022-06-22 Chugai Pharmaceutical Co Ltd Preparacion que contiene anticuerpo.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5954916B1 (ja) * 2015-04-14 2016-07-20 中外製薬株式会社 Il−31アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び/又は治療用医薬組成物

Also Published As

Publication number Publication date
KR20230114698A (ko) 2023-08-01
EP4252771A4 (en) 2024-10-23
JP2022095913A (ja) 2022-06-28
CA3199351A1 (en) 2022-06-02
TW202237182A (zh) 2022-10-01
WO2022114165A1 (ja) 2022-06-02
CN116829187A (zh) 2023-09-29
IL303159A (en) 2023-07-01
JPWO2022114165A1 (https=) 2022-06-02
WO2022113316A1 (ja) 2022-06-02
US20240084020A1 (en) 2024-03-14
AU2021385871A9 (en) 2024-05-02
JP7802601B2 (ja) 2026-01-20
AU2021385871A1 (en) 2023-06-22
CL2023001460A1 (es) 2023-12-01
JPWO2022113316A1 (https=) 2022-06-02
EP4252771A1 (en) 2023-10-04

Similar Documents

Publication Publication Date Title
MX2022007336A (es) Composiciones farmaceuticas intranasales de inhibidores de cgrp.
CA3148745A1 (en) Kras g12d inhibitors
MX2022007527A (es) Inhibidores de proteinas kras mutantes.
MX2023006164A (es) Inhibidor de la progresion de la fibrosis.
JOP20220267A1 (ar) مركبات أمينو ثيازول تحمل بدائل بصفتها مثبطات لـثنائي أسيل غليسرول كيناز زيتا لتنشيط المناعة
EP4360713A3 (en) Quinazoline derivatives as antitumor agents
SA521421645B1 (ar) بيرولينات إندماجية تعمل كمثبطات بروتياز نوعي لأوبيكويتين 30
PH12023552774A1 (en) Nek7 inhibitors
MX394961B (es) Composiciones para usarse en el tratamiento de enfermedades relacionadas con la interleucina 6
MX2022013984A (es) Inhibidores de cinasa 7 relacionada con el gen nunca en mitosis a (nek7).
CL2020000220A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
MX2024008629A (es) Derivados del azaindol y su uso como inhibidores de la erk-cinasa.
GEAP202215599A (en) Boron containing pde4 inhibitors
NZ745210A (en) Novel 2,3,5-substituted thiophene compound as protein kinase inhibitor
PH12022550843A1 (en) Thienopyrimidones as trpa1 inhibitors
AR123861A1 (es) Politerapia de antagonistas de unión al eje pd-1 e inhibidores de lrrk2
CL2020000221A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
UY27275A1 (es) Composiciones y metodos para aumentar la biodisponibilidad de agentes farmacéuticos
BR112022010143A2 (pt) Inibidores de ahr e usos respectivos
PH12022550846A1 (en) Thienopyrimidones as trpa1 inhibitors
JOP20170148A1 (ar) مثبطات Wnt لعلاج التليف
WO2021044231A3 (es) Compuestos de curcumina y aminoácidos básicos
MX2022006502A (es) Composiciones farmaceuticas.
ECSP22058286A (es) Agente profiláctico y/o terapéutico para la prostatitis crónica/síndrome de dolor pélvico crónico
WO2020013777A3 (en) Tablet formulations comprising metformin and sitagliptin